BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $40
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
BTIG analyst Julian Harrison maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $39 to $40.
BTIG analyst Julian Harrison maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $39 to $40.